# A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat

Source: https://onco.cc/trials/nct07822542/  
OnCo record `nct07822542` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of adebrelimab, cisplatin, carboplatin, pemetrexed and other drugs in lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07822542 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with a registry enrolment figure of 448 participants, started 2026-10-31 and due to reach its primary completion in 2030-05-31. Interventions recorded: HS-10370; Adebrelimab; Cisplatin; Carboplatin; Pemetrexed; Tislelizumab. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "* Interstitial lung disease (ILD)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07822542
- Phase: 3
- Setting: A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 448

## Sources

- ClinicalTrials.gov NCT07822542: https://clinicaltrials.gov/study/NCT07822542

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07822542.json